Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

J, Brandt; A, Khariouzov; J, Listing; H, Haibel; H, Sörensen; L, Grassnickel; M, Rudwaleit; J, Sieper; J, Braun

doi:10.1002/art.11017

Public

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Shared by NobleBlocks on Jun 1, 2003 • 12:00 AM UTC

Authors:

Brandt J

Khariouzov A

Listing J

Abstract

Objective There is increasing evidence that tumor necrosis factor alpha (TNFalpha) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti-TNFalpha therapy with etanercept, a 75-kd receptor fus...

Discussions